Novel Immuno-Oncology Target Screening Assays

Novel immuno-Oncology target Screening Assays

Cancer immunotherapy harnesses the body’s immune system to eliminate tumors by enhancing both innate and adaptive responses. Key effector cells include NK cells, cytotoxic T cells, B cells, and engineered platforms such as bispecific antibodies, BiTEs, and CAR-T cells. Understanding and modulating these mechanisms is critical to advancing next-generation immunotherapies.

At Axela Biosciences, we offer a comprehensive suite of biochemical and cell-based assays to evaluate immune function, screen novel therapeutic candidates, and accelerate immuno-oncology discovery.

✅ Target Expression Analysis

✅ Immune Cell-Mediated Cytotoxicity: T cell killing, NK cell killing

✅ Antigen Presentation Assays

✅ Immune Activation Assays: cytokine profiling, cell proliferation

✅ Immunomarker Detection

✅ Checkpoint Inhibitor Analysis: PD-1/PD-L1, CTLA-4, BTLA, TIGIT, GITR, OX40, CD28/CD40 pathways, and more

✅ CAR-T Cell Efficacy Testing

✅ Spatial Multiomic Analysis: proteomic and transcriptomic spatial profiling

Axela supports end-to-end immuno-oncology workflows — from biomarker discovery and immune cell assays to advanced data analysis and therapeutic outcomes.